Patiromer

So, so that's what we're gonna talk about because it, it's where the problem potentially lies, and in a way, we discussed that last w- time with finerenone, where, yeah, high potassiums might limit your use of a drug that's really protective for stopping or slowing down progression of chronic kidney disease.

I should highlight, Jeremy, that the current change is specific to Loquelma, and there is, of course, another potassium binder, Patiromer.

And Patiromer's, um, technology appraisal has not been reviewed, and its threshold is unchanged.

It still requires a confirmed potassium of six or above.

But I anticipate, for common sense reasons, that there should be or there will be similar change for Patiromer, as it just doesn't make sense to have two different thresholds for each.

So Jeremy, let's move on and make a start by considering what does this actually mean for how primary care will manage patients day to day?

Oh, right.